APP to Launch Imipenem and Cilastatin for Injection and Meropenem for Injection

APP announced that it will launch Imipenem and Cilastatin for Injection and Meropenem for Injection, generic versions of Primaxin IV (Merck) and Merrem IV (AstraZeneca), respectively. It is anticipated that Meropenem for injection will begin shipping the week of February 13, 2012, and that Imipenem and Cilastatin for Injection will ship in the next three to five weeks. APP's Imipenem and Cilastatin for Injection will be available in 250mg and 500mg single dose vials, while Meropenem for Injection will be available in 500mg and 1g single-dose vials. Both products are AP-rated, preservative-free, and bar-coded.

Imipenem and Cilastatin for Injection is indicated for the treatment of serious infections caused by susceptible strains of designated microorganisms. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, Imipenem and Cilastatin for Injection is used in the treatment of mixed infections and as a presumptive therapy prior to the identification of causative organisms.

Meropenem for Injection is indicated as a single-agent therapy for the treatment of skin and skin structure infections and intra-abdominal infections in adults and pediatric patients over three months, and for bacterial meningitis for pediatric patients over the age of three months.

For more information, call (800) 551-7176 or visit www.APPpharma.com.